Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union.
about
The changing landscape of biosimilars in rheumatologyRegulatory considerations in oncologic biosimilar drug developmentWaiving in vivo studies for monoclonal antibody biosimilar development: National and global challengesAugmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab).The Language of Biosimilars: Clarification, Definitions, and Regulatory AspectsBiosimilars advancements: Moving on to the future.Biosimilar regulation in the EU.Opportunities to Apply the 3Rs in Safety Assessment Programs.Rapid and improved characterization of therapeutic antibodies and antibody related products using IdeS digestion and subunit analysis.The road from development to approval: evaluating the body of evidence to confirm biosimilarity.The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC).Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.
P2860
Q26766515-2F4A796F-3893-46FB-894A-9886AE0AAD40Q27027947-8F563E1B-C94E-4F96-8EA6-7A8540CF34E3Q28079835-6EED942B-2534-46C7-B325-7EB69BE00907Q35856534-A93B65D1-47CE-41B1-99D2-B3A16964B23EQ37373244-6DCFE576-B84B-4BCB-A604-653F2FD675E9Q37732903-85B428F0-BFA7-4BC4-9FBB-2097F4CD6B03Q38364577-88476D82-8023-465C-AB8B-9D4F697217B2Q38570723-8D7C91FB-A648-40DD-B287-9E0A63C1F0F7Q38774773-7F072F97-C04F-45F3-BC30-7B84BB433504Q38828582-14CF3D0E-42D1-4CB2-B9E3-1F40E82FF923Q47950956-CDD80C85-DF6B-4F7D-9DB1-EFD0D743A817Q48502863-5BD2AD17-7911-49C4-BE76-37CCB1F7484BQ52651099-8E7B0329-6637-42D7-AC79-8BB4D84DE74F
P2860
Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Biosimilars entering the clini ...... m shift in the European Union.
@ast
Biosimilars entering the clini ...... m shift in the European Union.
@en
type
label
Biosimilars entering the clini ...... m shift in the European Union.
@ast
Biosimilars entering the clini ...... m shift in the European Union.
@en
prefLabel
Biosimilars entering the clini ...... m shift in the European Union.
@ast
Biosimilars entering the clini ...... m shift in the European Union.
@en
P2093
P2860
P356
P1476
Biosimilars entering the clini ...... m shift in the European Union.
@en
P2093
Christian K Schneider
Gabriele Reichmann
Jan Willem van der Laan
Karen De Smet
Leon A G J M van Aerts
P2860
P304
P356
10.4161/MABS.29848
P577
2014-01-01T00:00:00Z